Markets:

Overview

News

Currencies

International

Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

12.64 +0.11 (+0.88%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Novocure Hosts U.S. Sen. Maggie Hassan at Company’s Portsmouth Facility

August 10, 2022

From Novocure

Via Business Wire

NovoCure Earnings Perspective: Return On Capital Employed ↗

August 04, 2022

NovoCure (NASDAQ:NVCR) brought in sales totaling $140.87 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 416.63%, resulting in a loss of $24.01 million.

Via Benzinga

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: NovoCure Q2 Earnings ↗

July 28, 2022

NovoCure (NASDAQ:NVCR) reported its Q2 earnings results on Thursday, July 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

NovoCure: Q1 Earnings Insights ↗

April 28, 2022

NovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Novocure's TTFields Show Improved Progression-Free, Overall Survival Over Matched-Control ↗

March 25, 2022

Novocure Ltd (NASDAQ: NVCR)

Via Benzinga

Novocure Reports Second Quarter 2022 Financial Results

July 28, 2022

From Novocure

Via Business Wire

Novocure Announces Recipients of 4th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

July 27, 2022

From Novocure

Via Business Wire

Biotech Stocks To Watch And Pharma Industry News ↗

July 08, 2022

Track the latest trends and leading stocks in the biotech and pharmaceutical industries.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2022 ↗

July 05, 2022

Upgrades

Via Benzinga

Novocure to Report Second Quarter 2022 Financial Results

July 01, 2022

From Novocure

Via Business Wire

Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗

June 21, 2022

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid...

Via Benzinga

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

June 21, 2022

From Novocure

Via Business Wire

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

June 03, 2022

From Novocure

Via Business Wire

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review ↗

May 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Novocure Announces Clinical Collaboration with MSD on a Registrational-Intent Study to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Newly Diagnosed Glioblastoma

May 26, 2022

From Novocure

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2022 ↗

May 16, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗

April 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Novocure Reports First Quarter 2022 Financial Results

April 28, 2022

From Novocure

Via Business Wire

Novocure Hosts Ceremonial Groundbreaking with New Hampshire Governor Chris Sununu

April 19, 2022

From Novocure

Via Business Wire

Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields

April 08, 2022

From Novocure

Via Business Wire

Novocure to Report First Quarter 2022 Financial Results

April 01, 2022

From Novocure

Via Business Wire

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗

March 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial

March 24, 2022

From Novocure

Via Business Wire

Novocure Announces Favorable Recommendation to Continue the Phase 3 Pivotal INNOVATE-3 Study of Tumor Treating Fields in Ovarian Cancer

March 23, 2022

From Novocure

Via Business Wire

Up On Bad News ↗

March 22, 2022

Despite the plane crash in China, Boeing's stock is up today.

Via Talk Markets

Lucky Day ↗

March 21, 2022

Today Alleghany rose nearly 25% because it is being bought by Berkshire Hathaway, Warren Buffett's fund.

Via Talk Markets

World Markets News For Friday ↗

March 18, 2022

Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%.

Via Talk Markets

Novocure Founder Yoram Palti Wins 2022 Israel Prize in Entrepreneurship and Technological Innovation

February 28, 2022

From Novocure

Via Business Wire

Novocure’s General Counsel Resigns After 10 Years of Service

February 24, 2022

From Novocure

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

NovoCure Limited - Ordinary Shares (NQ:NVCR)

All News about NovoCure Limited - Ordinary Shares

Starting at $3.75/week.

Subscribe Today